Kytogenics Logo
Home | Contact Us | Site Map.
Kytogenics Pharmaceuticals, Inc.

Kytogenics_Welcome

Proprietary protection is very important for companies involved in the biomedical industry. Kytogenics' success therefore will depend in part on its ability to obtain and enforce protection for its products under United States and foreign patent laws and other intellectual property laws, preserve confidentiality of its trade secrets and operate without infringing the proprietary rights of third parties. Kytogenics' policy is to file patent applications in the United States and/or foreign jurisdictions to protect technology, inventions and improvements to its inventions that are considered important to the development of its business. Kytogenics will also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop a competitive position.

Over the past number of years Kytogenics has filed patents to protect its Intellectual Property and it plans to continue to extend its existing portfolio as opportunities arise. A short description of some of the Kytogenics' Patent Portfolio of twelve U.S. issued patents and one published patent applications follows:

  • Method and Composition for treatment of a Mucosal Disorder.  US patent #7,691,830 B2 was issued Apr 6, 2010 and describes methods of testing a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease, inflammatory bowel disease or colitis, by administering medicament containing a sulfated chitinous polymer administered topically are described.  Pharmaceutical compositions containing the sulfate chitinous polymer are also described.  A continuation of this patent, US2010/0190743 A1 was published on July 29, 2010.
  • N-acylated chitinous polymers and methods of use thereof.  US Patents # 7,456,267 and # 8,039,448 were issued on Nov 25, 2008 and October 18, 2011 respectively.  The invention pertains to N-acetylated, N, O-carboxyalkyl-chitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.
  • Adhesive N,O-Carboxymethyl Chitosan Coatings Which Inhibit Attachment of Substrate-Dependent Cells and Proteins. U.S. patents #6,645,947, #6,894,035 and #7,238,678 were issued Nov 11, 2003, May 17, 2005 and July 3, 2008 respectively and describe a MACC composition which is bioadherent to synthetic materials and mammalian tissues and provide a method of inhibiting the attachment of proteins and substrate-dependent cells (e.g. fibroblasts, macrophages, epithelial cells).
  • Methods of Drug Delivery Using Sulphated Chitinous Polymers. U.S. patents #7,265,097 and #8,017,595 were issued September 4, 2007 and September 13, 2011 respectively.  The patents provide methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent.  The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier. 
  • Malleable Paste for Filling Bone Defects. U.S. patent #RE39,587E was issued on April 23, 2007. The patent is for a malleable bone putty and flowable gel composition for application to a bone defect site to promote new bone growth at the site.

  • Adherent N,O-Carboxymethyl Chitosan Drug Delivery Devices for Moist Tissue and Methods of Their Use. US patent #6,809,085 was issued on October 26, 2004.  This patent relates to drug delivery devices for moist tissues, in particular mucosal tissue and tissue in the serous cavities, as well as a method of its use.  The devices, which contain NOCC, are adherent to the mucosal tissue, allowing localized drug delivery.  The devices are particularly useful in vaginal, buccal and ocular devices.
  • Chitin Hydrogels, Methods of Their Production and Use. This US patent #6,124,273 was issued on September 26, 2000 and is a joint patent by Kytogenics, the American Red Cross and the Coalition for Hemophilia B. The patent claims the use of NOCC to deliver therapeutic blood proteins, growth factors, and other agents.
  • Covalently Linked N,O-Carboxymethyl Chitosan and Uses Thereof. U.S. patent #5,888,988 was issued on March 30, 1999 and describes the direct coupling of a wide range of therapeutic and non-active compounds to NOCC as well as a new hydrogel formed by coupling NOCC to itself, without bridging or cross-linking agents.